Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 11,257 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Neonate Clear all

Conditions: Phenylketonuria
Interventions: SYNB1618, SYNB1934; Drug
Lead sponsor: Synlogic; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 11
States / cities: Aurora, Colorado • Boca Raton, Florida • Gainesville, Florida + 7 more

Conditions: Epithelial Ovarian Carcinoma, Pancreas Adenocarcinoma
Interventions: Electronic Decision Aid, Pre-Test Genetic Counseling; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts • Danvers, Massachusetts

Conditions: Physical Activity
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Hereditary Angioedema (HAE)
Interventions: CINRYZE 500, CINRYZE 1000; Biological
Lead sponsor: Shire; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Colorado Springs, Colorado • Las Vegas, Nevada • Eugene, Oregon

Conditions: Wrinkle, Pigmentation, Skin Laxity, Skin Scarring
Interventions: Treatment with BTL-785F; Device
Lead sponsor: BTL Industries Ltd.; Industry
Eligibility: 22 Years and older
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Greenwood Village, Colorado • Chevy Chase, Maryland • Birmingham, Michigan

Conditions: Ras/MAPK Pathway Vascular Anomalies, Vascular Anomalies, Vascular Anomaly
Interventions: Trametinib; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Months to 30 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Lysosomal Acid Lipase Deficiency, Wolman Disease
Interventions: Not listed
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 7
States / cities: Los Angeles, California • Palo Alto, California • Minneapolis, Minnesota + 2 more

Conditions: Atopic Dermatitis
Interventions: Online Teledermatology Care, Conventional in Office Care; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 4 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Cystic Fibrosis
Interventions: Omadacycline Injection [Nuzyra], Omadacycline Oral Tablet [Nuzyra]; Drug
Lead sponsor: Paul Beringer; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Netherton Syndrome
Interventions: QRX003, 4% Lotion; Drug
Lead sponsor: Quoin Pharmaceuticals; Industry
Eligibility: 14 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cancer
Interventions: caspofungin acetate, liposomal amphotericin B; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: New York, New York

Conditions: Primary Immunodeficiency Diseases (PID)
Interventions: HYQVIA; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 16 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 30
States / cities: Bakersfield, California • Irvine, California • Redondo Beach, California + 24 more

Conditions: Head and Neck (HNSCC), Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Head and Neck Squamous Cell Carcinoma, Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
Interventions: Aspirin, Paclitaxel; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Arteriovenous Fistula
Interventions: FLEX Scoring Catheter with Lutonix DCB; Combination Product
Lead sponsor: VentureMed Group Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Orangeburg, South Carolina

Conditions: Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: busulfan, melphalan, methotrexate, tacrolimus, allogeneic bone marrow transplantation; Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Genetic Disease
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 18 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 2
States / cities: Bethesda, Maryland • Strasburg, Pennsylvania

Conditions: Tourette Syndrome
Interventions: Transcranial Magnetic Stimulation, Comprehensive behavioral intervention; Device · Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 85 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Congenital Disorders
Interventions: Not listed
Lead sponsor: Children's Healthcare of Atlanta; Other
Eligibility: Up to 21 Years · Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Limb-Girdle Muscular Dystrophy
Interventions: Deflazacort; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 8
States / cities: Atlanta, Georgia • Iowa City, Iowa • Kansas City, Kansas + 5 more

Conditions: Familial Hypercholesterolemia
Interventions: Evolocumab; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Sickle Cell Disease
Interventions: Deferoxamine, Deferasirox, Deferiprone, Echocardiography, Electrocardiogram (ECG); Drug · Device
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Fairfax, Virginia • Falls Church, Virginia

Conditions: Mitochondrial Disorders, Li-Fraumeni Syndrome, Carriers of p53 Mutation
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: Milene Saavedra; Other
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Neurofibromatosis 1 (NF1), Neurofibromatosis Type I
Interventions: GentleMax Pro (with skin cooling), GentleMax Pro (without skin cooling); Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Efficacy and Safety of SYNB1618 and SYNB1934 in Adult Patients With Phenylketonuria

Genetic Testing Decision Aid

Validation of Objective Measures of Place-Based Physical Activity

Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema

Device for Improving Skin Quality and Texture on the Face and Neck

24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs

A Retrospective Natural History Study of Patients With Lysosomal Acid Lipase Deficiency/Wolman Phenotype

Comparison Between Asynchronous Online Care Model With Usual In Office Care for the Management of Atopic Dermatitis

Pharmacokinetics of Omadacycline in Cystic Fibrosis

Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome

Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment

Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)

Aspirin and PAClitaxel in Head & Neck Squamous Cell Carcinoma

FLEX®-DCB Dialysis ACCESS Stenosis Study

Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer

Genetic Studies in the Amish and Mennonites

Combined CBIT and rTMS to Improve Tourette's Syndrome

Infant Medical Records: Case Report Proposal

A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)

Impact of LDL-cholesterol Lowering on Platelet Activation

Early Screening and Treatment of Heart Complication in Sickle Cell Disease

Role of p53 Gene in Metabolism Regulation in Patients With Li-Fraumeni Syndrome

A Novel Assay to Quantify Treatment Response in Cystic Fibrosis (CF)

Assessing the Efficacy of Repeat, Monthly Treatments of Alexandrite Laser for NF1-associated Cutaneous Neurofibromas (cNFs)